腹腔化学治疗用于盆腔和腹腔恶性肿瘤的进展
摘要
<正>晚期盆腔和腹腔恶性肿瘤往往会发生腹腔内广泛转移和恶性腹水,除手术治疗外,全身静脉化学治疗(以下简称化疗)是主要的治疗手段之一,但临床效果不理想,原因为静脉化疗药物不能直接作用于腹腔游离癌细胞(intraperitoneal free cancer cells,IFCCs),且种植于腹膜表面的微小癌灶缺乏新生血管,难以形成有效的药物浓度环境。腹腔化疗将化疗药物灌注于腹腔,直接作用于腹腔肿瘤细胞,具有一定的药物代谢动力学优势,成为临床治疗盆
引文
[1] WEISBERGER A S, LEVINE B, STORAASLI J P. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin[J]. J Am Med Assoc, 1955, 159(18): 1704-1707.
[2] SUGARBAKER P H. It’s what the surgeon doesn’t see that kills the patient[J]. J Nippon Med Sch, 2000, 67(1): 5-8.
[3] 姬忠贺, 孙建华, 武海涛, 等. 腹腔热灌注化疗对腹腔游离癌细胞杀灭效果的评价[J]. 中国肿瘤临床, 2015, 42(19): 963-968.
[4] BANDO E, YONEMURA Y, TAKESHITA Y, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma[J]. Am J Surg, 1999, 178(3): 256-262.
[5] KANO Y, KOSUGI S, ISHIKAWA T, et al. Prognostic significance of peritoneal lavage cytology at three cavities in patients with gastric cancer[J]. Surgery, 2015, 158(6): 1581-1589.
[6] LEE S D, RYU K W, EOM B W, et al. Prognostic significance of peritoneal washing cytology in patients with gastric cancer[J]. Br J Surg, 2012, 99(3): 397-403.
[7] NISHIKAWA T, WATANABE T, SUNAMI E, et al. Prognostic value of peritoneal cytology and the combination of peritoneal cytology and peritoneal dissemination in colorectal cancer[J]. Dis Colon Rectum, 2009, 52(12): 2016-2021.
[8] ZUNA R E, BEHRENS A. Peritoneal washing cytology in gynecologic cancers:long-term follow-up of 355 patients[J]. J Natl Cancer Inst, 1996, 88(14): 980-987.
[9] HAMILTON C A, BEREK J S. Intraperitoneal chemotherapy for ovarian cancer[J]. Curr Opin Oncol, 2006, 18(5): 507-515.
[10] SUGARBAKER P H, YU W, YONEMURA Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer[J]. Semin Surg Oncol, 2003, 21(4): 233-248.
[11] ELIAS D, DELPERRO J R, SIDERIS L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials[J]. Ann Surg Oncol, 2004, 11(5): 518-521.
[12] MAHTEME H, HANSSON J, BERGLUND A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study[J]. Br J Cancer, 2004, 90(2): 403-407.
[13] PARK S Y, CHOI G S, PARK J S, et al. Efficacy of early postoperative intraperitoneal chemotherapy after complete surgical resection of peritoneal metastasis from colorectal cancer: a case-control study from a single center[J]. Ann Surg Oncol, 2016, 23(7): 2266-2273.
[14] CASHIN P H, MAHTEME H, SP?NG N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial[J]. Eur J Cancer, 2016, 53: 155-162.
[15] 崔欢, 张菊新. 高精度持续循环腹腔热灌注化疗联合静脉化疗治疗卵巢癌的临床研究[J]. 国际妇产科学杂志, 2014, 41(1): 77-79.
[16] ARMSTRONG D K, BUNDY B, WENZEL L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. N Engl J Med, 2006, 354(1): 34-43.
[17] GOURLEY C, WALKER J L, MACKAY H J. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer[J]. Am Soc Clin Oncol Educ Book, 2016, 35: 143-151.
[18] TEWARI D, JAVA J J, SALANI R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study[J]. J Clin Oncol, 2015, 33(13): 1460-1466.
[19] MARKMAN M, BUNDY B N, ALBERTS D S, et al. Phase Ⅲ trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage Ⅲ ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2001, 19(4): 1001-1007.
[20] CASCALES-CAMPOS P, GIL J, GIL E, et al. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage ⅢC-Ⅳ ovarian cancer. Critical analysis in elderly patients[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 179: 88-93.
[21] PAVLOV M J, KOVACEVIC P A, CERANIC M S, et al. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer—12-year single center experience[J]. Eur J Surg Oncol, 2009, 35(11): 1186-1191.
[22] 张玉勤, 俞绍音, 葛勇前, 等. 卵巢癌腹腔化疗的药代动力学特征[J]. 中国癌症杂志, 2002, 12(2): 130-132.
[23] 李雁, 周云峰, 梁寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识[J]. 中国肿瘤临床, 2015, 42(4): 198-206.
[24] SPRATT J S, ADCOCK R A, MUSKOVIN M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy[J]. Cancer Res, 1980, 40(2): 256-260.
[25] GLEHEN O, SCHREIBER V, COTTE E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer[J]. Arch Surg, 2004, 139(1): 20-26.
[26] YONEMURA Y, KAWAMURA T, BANDOU E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion[J]. Br J Surg, 2005, 92(3): 370-375.
[27] SUN J, SONG Y, WANG Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials[J/OL]. BMC Cancer, 2012, 12: 526[2012-11-16]. https://doi.org/10.1186/1471-2407-12-526.
[28] VERWAAL V J, VAN RUTH S, DE BREE E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer[J]. J Clin Oncol, 2003, 21(20): 3737-3743.
[29] ZIVANOVIC O, ABRAMIAN A, KULLMANN M, et al. HIPEC ROC Ⅰ: a phase Ⅰ study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer[J]. Int J Cancer, 2015, 136(3): 699-708.
[30] CASCALES-CAMPOS P A, GIL J, GIL E, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage ⅢC-Ⅳ ovarian cancer[J]. Ann Surg Oncol, 2014, 21(7): 2383-2389.
[31] SAFRA T, GRISARU D, INBAR M, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study[J]. J Surg Oncol, 2014, 110(6): 661-665.
[32] SPILIOTIS J, HALKIA E, LIANOS E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase Ⅲ study[J]. Ann Surg Oncol, 2015, 22(5): 1570-1575.
[33] TAN W J, WONG J F, CHIA C S, et al. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an Asian perspective[J]. Ann Surg Oncol, 2013, 20(13): 4219-4223.
[34] DI GIORGIO A, DE IACO P, DE SIMONE M, et al. Cytoreduction (Peritonectomy Procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases[J]. Ann Surg Oncol, 2017, 24(4): 914-922.
[35] 腹腔热灌注化疗技术临床应用专家协作组. 腹腔热灌注化疗技术临床应用专家共识(2016版)[J/CD]. 消化肿瘤杂志(电子版), 2016, 8(3): 125-129.
[36] ARMSTRONG D K, BUNDY B, WENZEL L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. N Engl J Med, 2006, 354(1): 34-43.
[37] DE BREE E, HELM C W. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data[J]. Expert Rev Anticancer Ther, 2012, 12(7): 895-911.
[38] 梁寒. 进展期胃癌的腹腔缓释化疗[J]. 中华胃肠外科杂志, 2012, 15(2): 116-117.
[39] 陈伟强, 付立梧. 肿瘤腹腔化疗的药物选择原则[J]. 中华普通外科杂志, 2010, 25(10): 864.
[2] SUGARBAKER P H. It’s what the surgeon doesn’t see that kills the patient[J]. J Nippon Med Sch, 2000, 67(1): 5-8.
[3] 姬忠贺, 孙建华, 武海涛, 等. 腹腔热灌注化疗对腹腔游离癌细胞杀灭效果的评价[J]. 中国肿瘤临床, 2015, 42(19): 963-968.
[4] BANDO E, YONEMURA Y, TAKESHITA Y, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma[J]. Am J Surg, 1999, 178(3): 256-262.
[5] KANO Y, KOSUGI S, ISHIKAWA T, et al. Prognostic significance of peritoneal lavage cytology at three cavities in patients with gastric cancer[J]. Surgery, 2015, 158(6): 1581-1589.
[6] LEE S D, RYU K W, EOM B W, et al. Prognostic significance of peritoneal washing cytology in patients with gastric cancer[J]. Br J Surg, 2012, 99(3): 397-403.
[7] NISHIKAWA T, WATANABE T, SUNAMI E, et al. Prognostic value of peritoneal cytology and the combination of peritoneal cytology and peritoneal dissemination in colorectal cancer[J]. Dis Colon Rectum, 2009, 52(12): 2016-2021.
[8] ZUNA R E, BEHRENS A. Peritoneal washing cytology in gynecologic cancers:long-term follow-up of 355 patients[J]. J Natl Cancer Inst, 1996, 88(14): 980-987.
[9] HAMILTON C A, BEREK J S. Intraperitoneal chemotherapy for ovarian cancer[J]. Curr Opin Oncol, 2006, 18(5): 507-515.
[10] SUGARBAKER P H, YU W, YONEMURA Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer[J]. Semin Surg Oncol, 2003, 21(4): 233-248.
[11] ELIAS D, DELPERRO J R, SIDERIS L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials[J]. Ann Surg Oncol, 2004, 11(5): 518-521.
[12] MAHTEME H, HANSSON J, BERGLUND A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study[J]. Br J Cancer, 2004, 90(2): 403-407.
[13] PARK S Y, CHOI G S, PARK J S, et al. Efficacy of early postoperative intraperitoneal chemotherapy after complete surgical resection of peritoneal metastasis from colorectal cancer: a case-control study from a single center[J]. Ann Surg Oncol, 2016, 23(7): 2266-2273.
[14] CASHIN P H, MAHTEME H, SP?NG N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial[J]. Eur J Cancer, 2016, 53: 155-162.
[15] 崔欢, 张菊新. 高精度持续循环腹腔热灌注化疗联合静脉化疗治疗卵巢癌的临床研究[J]. 国际妇产科学杂志, 2014, 41(1): 77-79.
[16] ARMSTRONG D K, BUNDY B, WENZEL L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. N Engl J Med, 2006, 354(1): 34-43.
[17] GOURLEY C, WALKER J L, MACKAY H J. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer[J]. Am Soc Clin Oncol Educ Book, 2016, 35: 143-151.
[18] TEWARI D, JAVA J J, SALANI R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study[J]. J Clin Oncol, 2015, 33(13): 1460-1466.
[19] MARKMAN M, BUNDY B N, ALBERTS D S, et al. Phase Ⅲ trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage Ⅲ ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2001, 19(4): 1001-1007.
[20] CASCALES-CAMPOS P, GIL J, GIL E, et al. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage ⅢC-Ⅳ ovarian cancer. Critical analysis in elderly patients[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 179: 88-93.
[21] PAVLOV M J, KOVACEVIC P A, CERANIC M S, et al. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer—12-year single center experience[J]. Eur J Surg Oncol, 2009, 35(11): 1186-1191.
[22] 张玉勤, 俞绍音, 葛勇前, 等. 卵巢癌腹腔化疗的药代动力学特征[J]. 中国癌症杂志, 2002, 12(2): 130-132.
[23] 李雁, 周云峰, 梁寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识[J]. 中国肿瘤临床, 2015, 42(4): 198-206.
[24] SPRATT J S, ADCOCK R A, MUSKOVIN M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy[J]. Cancer Res, 1980, 40(2): 256-260.
[25] GLEHEN O, SCHREIBER V, COTTE E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer[J]. Arch Surg, 2004, 139(1): 20-26.
[26] YONEMURA Y, KAWAMURA T, BANDOU E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion[J]. Br J Surg, 2005, 92(3): 370-375.
[27] SUN J, SONG Y, WANG Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials[J/OL]. BMC Cancer, 2012, 12: 526[2012-11-16]. https://doi.org/10.1186/1471-2407-12-526.
[28] VERWAAL V J, VAN RUTH S, DE BREE E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer[J]. J Clin Oncol, 2003, 21(20): 3737-3743.
[29] ZIVANOVIC O, ABRAMIAN A, KULLMANN M, et al. HIPEC ROC Ⅰ: a phase Ⅰ study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer[J]. Int J Cancer, 2015, 136(3): 699-708.
[30] CASCALES-CAMPOS P A, GIL J, GIL E, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage ⅢC-Ⅳ ovarian cancer[J]. Ann Surg Oncol, 2014, 21(7): 2383-2389.
[31] SAFRA T, GRISARU D, INBAR M, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study[J]. J Surg Oncol, 2014, 110(6): 661-665.
[32] SPILIOTIS J, HALKIA E, LIANOS E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase Ⅲ study[J]. Ann Surg Oncol, 2015, 22(5): 1570-1575.
[33] TAN W J, WONG J F, CHIA C S, et al. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an Asian perspective[J]. Ann Surg Oncol, 2013, 20(13): 4219-4223.
[34] DI GIORGIO A, DE IACO P, DE SIMONE M, et al. Cytoreduction (Peritonectomy Procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases[J]. Ann Surg Oncol, 2017, 24(4): 914-922.
[35] 腹腔热灌注化疗技术临床应用专家协作组. 腹腔热灌注化疗技术临床应用专家共识(2016版)[J/CD]. 消化肿瘤杂志(电子版), 2016, 8(3): 125-129.
[36] ARMSTRONG D K, BUNDY B, WENZEL L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. N Engl J Med, 2006, 354(1): 34-43.
[37] DE BREE E, HELM C W. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data[J]. Expert Rev Anticancer Ther, 2012, 12(7): 895-911.
[38] 梁寒. 进展期胃癌的腹腔缓释化疗[J]. 中华胃肠外科杂志, 2012, 15(2): 116-117.
[39] 陈伟强, 付立梧. 肿瘤腹腔化疗的药物选择原则[J]. 中华普通外科杂志, 2010, 25(10): 864.